Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10899561 | Cancer Letters | 2015 | 7 Pages |
Abstract
- The 3 clinical trials can't be compared effectively because of concrete differences.
- Bevacizumab (beva) is non-toxic as monotherapy and is a chemosensitizer.
- Combining bevacizumab and highly toxic doses of chemotherapy masks beva's efficacy.
- Re-evaluate the current model of highly toxic doses of chemo with bevacizumab.
- Metronomic dosing (frequent lower doses of chemo) with beva may be more effective.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jennifer A. Afranie-Sakyi, Giannoula Lakka Klement,